MannKind Corp. (MNKD) Reports Q1 2026 Total Revenues of $90.2M

2 days ago 3

Maham Fatima

Sun, May 17, 2026 astatine 11:50 PM CDT 2 min read

MannKind Corporation (NASDAQ:MNKD) is 1 of the best NASDAQ stocks nether $5 to bargain close now. On May 6, MannKind reported full revenues of $90.2 cardinal for Q1 2026, marking a 15% summation compared to Q1 2025. This maturation was driven by $15.5 cardinal successful nett income from Furoscix and a 9% summation successful Tyvaso DPI royalties from United Therapeutics, which offset a 20% driblet successful collaboration revenues. Operating costs grew, with R&D expenses climbing 56% to $17.2 cardinal and SG&A expenses rising 116% to $54.1 cardinal owed to the acquisition of scPharma and commercialized motorboat preparations.

On the regulatory front, MannKind is approaching 2 cardinal FDA enactment dates. The PDUFA day for the Afrezza inhaled insulin pediatric denotation is acceptable for May 29, portion the Furoscix ReadyFlow Autoinjector has a people PDUFA day of July 26. To enactment these imaginable commercialized expansions, the institution has already built retired its motorboat infrastructure and aligned its field-based teams.

In its improvement pipeline, MannKind Corporation (NASDAQ:MNKD) completed enrollment for the Phase 1b proceedings of Nintedanib DPI (MNKD-201) for idiopathic pulmonary fibrosis (IPF), with a Phase 2 proceedings expected to enroll its archetypal diligent successful Q2 2026. Additionally, the institution expanded its collaboration with United Therapeutics for Ralinepag DPI (MNKD-1501), receiving a $5 cardinal outgo to accelerate its development. Formulation enactment besides continues for Bumetanide DPI (MNKD-701) to dainty edema associated with bosom and kidney disease.

MannKind Corp. (MNKD) Reports Q1 2026 Total Revenues of $90.2M

15 African Countries with the Best Doctors

MannKind Corporation (NASDAQ:MNKD) is simply a biopharmaceutical institution focused connected processing and commercializing innovative inhaled therapeutic products and devices for those surviving with endocrine and orphan lung diseases.

While we admit the imaginable of MNKD arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.

Disclosure: None. Follow Insider Monkey connected Google News.

Read Entire Article